Claims
- 1. An isolated polypeptide comprising SEQ ID NO: 8.
- 2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:(a)sequences having at least 75% identity to SEQ ID NO: 8; (b)sequences having at least 90% identity to SEQ ID NO: 8; and (c)sequences having at least 95% identity to SEQ ID NO: 8, wherein the polypeptide is capable of eliciting and/or enhancing an immune response.
- 3. An immunogenic composition comprising at least one polypeptide according to claim 2 and a heterologous antigen.
- 4. The immunogenic composition of claim 3, wherein the heterologous antigen is selected from the group consisting of: tumor-specific antigens, infectious disease antigens and autoantigens.
- 5. A fusion protein comprising at least one polypeptide according to claim 2 and a heterologous antigen.
- 6. The fusion protein of claim 5, wherein the heterologous antigen is selected from the group consisting of: tumor-specific antigens, infectious disease antigens and autoantigens.
- 7. An isolated polypeptide encoded by SEQ ID NO: 4.
- 8. An immunogenic composition comprising at least one polypeptide according to any one of claims 1 and 7 and a heterologous antigen.
- 9. The immunogenic composition of claim 8, wherein the heterologous antigen is selected from the group consisting of: tumor-specific antigens, infectious disease antigens and autoantigens.
- 10. A fusion protein comprising at least one polypeptide according to any one of claims 1 and 7 and a heterologous antigen.
- 11. The fusion protein of claim 10, wherein the heterologous antigen is selected from the group consisting of: tumor-specific antigens, infectious disease antigens and autoantigens.
REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. patent application Ser. No. 09/455,960, filed Dec. 6, 1999, now U.S. Pat. No. 6,361,776.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/455960 |
Dec 1999 |
US |
Child |
10/051325 |
|
US |